@article{87ea7c139309492d81a14599b365d99a,
title = "Vestibular evoked myogenic potential testing Payment policy review for clinicians and payers",
abstract = "Purpose of review A recent American Academy of Neurology Evidence-Based Practice Guideline on vestibular myogenic evoked potential (VEMP) testing has described superior canal dehiscence syndrome (SCDS) and evaluated the merits of VEMP in its diagnosis. SCDS is an uncommon but now well-recognized cause of dizziness and auditory symptoms. This article familiarizes health care providers with this syndrome and the utility and shortcomings of VEMP as a diagnostic test and also explores payment policies for VEMP. Recent findings In carefully selected patients with documented history compatible with the SCDS, both high-resolution temporal bone CT scan and VEMP are valuable aids for diagnosis. Payers might be unfamiliar with both this syndrome and VEMP testing. Summary It is important to raise awareness of VEMP and its possible indications and the rationale for coverage of VEMP testing. Payers may not be readily receptive to VEMP coverage if this test is used in an undifferentiated manner for all common vestibular and auditory symptoms.",
author = "Fife, {Terry D.} and Saty Satya-Murti and Burkard, {Robert F.} and Carey, {John P.}",
note = "Funding Information: T.D. Fife serves on 2 data safety and monitoring boards for NIH-sponsored studies. S. Satya-Murti has participated in telephone consultations or in-person medical advisory board meetings for Evidera (formerly United BioSource Corporation UBC), Simon-Kucher consultants, Baxter, CB Partners, Avalere LLC, Medtronic, 1798 Consultants, Par-exel, DeciBio, and AbbVie; has received funding for travel from United BioSource Corporation UBC (2010-13), AstraZeneca, Avalere LLC, Evidera consulting group, Covidien, Michael J. Fox Foundation, Foley Hoag LLP, Baxter, and AbbVie; serves on the editorial board of Neurology{\textregistered}: Clinical Practice; served on the American Academy of Neurology Payment Policy Subcommittee; and served as panelist and later (2010-2011) Vice-Chair CMS-MEDCAC (Medicare Evidence Development and Coverage Advisory Committee). For the duration of the MEDCAC meeting, usually 1-2 days, S. Satya Murti was considered a Special Government Employee (SGE). R.F. Burkard serves on an Advisory Board for the NCRAR at the Portland VA Hospital; is a member of the Board of Directors for the American Auditory Society and a member of the Health Care Economics Committee for the American Speech-Language-Hearing Association; and has served as a paid consultant on a grant given to the Marine Mammal Foundation. J.P. Carey serves on a DSMB for NIH-funded clinical trial; has received funding for travel from Otonomy; serves as an Associate Editor for Audiology and Neurotology; has served as a consultant for Pfizer and Otonomy; and performs vestibular testing interpretation (<10% effort; VEMPs are a fraction of that); if recommendations were fully implemented, they would actually reduce VEMP revenue; and receives research support from Otonomy and NIH/NIDCD. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp. Publisher Copyright: Copyright {\textcopyright} 2018 American Academy of Neurology.",
year = "2018",
doi = "10.1212/CPJ.0000000000000430",
language = "English (US)",
volume = "8",
pages = "129--134",
journal = "Neurology: Clinical Practice",
issn = "2163-0402",
publisher = "Lippincott Williams and Wilkins",
number = "2",
}